University of Texas's MD Anderson Cancer: Combination Therapy Achieves High Rates of Response for Patients With Acute Lymphoblastic Leukemia
May 19, 2021
May 19, 2021
HOUSTON, Texas, May 19 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center. The study may support a regimen to produce complete remission with fro . . .
A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center. The study may support a regimen to produce complete remission with fro . . .